Q-omics provides the consensus-scored CRLF2 profile across patient tissues and cancer cell-line models. CRLF2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CRLF2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CRLF2 RNA expression shows 12,964 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, THCA, and KIRP as cancer lineages where CRLF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRLF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRLF2 survival associations across molecular data types. CRLF2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRLF2 RNA expression–survival associations across cancer types. High CRLF2 expression shows unfavorable associations in KIRP and SCLC, but favorable associations in HNSC, SKCM, CESC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CRLF2 RNA expression.
This table summarizes CRLF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CRLF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRLF2 shows lower tumor expression in BLCA and LUSC and higher tumor expression in THCA, KIRC, LIHC and LUAD. The THCA box plot shows higher CRLF2 RNA expression in tumor versus normal tissue (log2 FC = +3.706, t-test p < 0.001).
This table shows molecular features associated with CRLF2 in patient tissues and cancer cell lines. In patient samples, CRLF2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CRLF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
